Dr. Stone is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
44 Binney St
Boston, MA 02115Phone+1 617-632-2214Fax+1 617-632-2933
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1984 - 1987
- Brigham and Women's HospitalResidency, Internal Medicine, 1981 - 1984
- Harvard Medical SchoolClass of 1981
Certifications & Licensure
- FL State Medical License 2022 - Present
- NH State Medical License 2024 - 2026
- RI State Medical License 2022 - 2026
- VT State Medical License 2023 - 2026
- MA State Medical License 1984 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase Start of enrollment: 1999 Mar 01
- Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia Start of enrollment: 1999 Apr 01
- Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2001 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 589 citationsCPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute My...Jeffrey E. Lancet, Geoffrey L. Uy, Jorge E. Cortes, Laura F. Newell, Tara L. Lin
Journal of Clinical Oncology. 2018-07-19 - 995 citationsInternational Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.Daniel A Arber, Attilio Orazi, Robert P Hasserjian, Michael J Borowitz, Katherine R Calvo
Blood. 2022-09-15 - 314 citationsPrognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid LeukemiaKrzysztof Mrózek, Guido Marcucci, Deedra Nicolet, Kati Maharry, Heiko Becker
Journal of Clinical Oncology. 2012-12-20
Journal Articles
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AMLDaniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
- NF1 Mutations Are Recurrent in Adult Acute Myeloid Leukemia and Confer Poor OutcomeEunice S Wang, Bayard L Powell, Richard M Stone, John C Byrd, Clara D Bloomfield, Alice Mims, Andrew J Carroll, Jonathan E Kolitz, James S Blachly, Nature
Abstracts/Posters
- Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leu...Richard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Feasibility and Impact of Embedded Geriatric Consultation for Frail Older Adults with Blood Cancer: A Randomized Controlled TrialRichard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older AdultsRichard Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Crenolanib versus midostaurin combined with induction and consolidation chemotherapy in newly diagnosed mutated AML.ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
- Data + Perspectives: Exploring the Role of Novel Agents and Emerging Strategies in the Management of Acute Myeloid Leukemia61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Pre...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Join now to see all
Other
- Older Adults with Acute Myeloid Leukemia Treated with Intensive Chemotherapy: “Old” Prognostic Algorithms May Not ApplyRichard Stone, MD, Haematologica
https://www.doximity.com/articles/b27bba2a-b21b-4ce6-8922-56d9b6b9b894
UpToDate, Wolters Kluwer Health - 2013-04-10
Authored Content
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationJune 2017
Press Mentions
- Could Aspirin Avert Bad Outcomes in Leukemia?September 9th, 2024
- Journal Honors Rahul S. Vedula, MD, as Recipient of the 2020 Journal of Clinical Oncology Young Investigator AwardJune 25th, 2020
- Genomic Advances Pave the Way for New Therapies in AMLMarch 1st, 2017
Grant Support
- Third Bone Marrow Failure Disease Scientific SymposiumNational Heart, Lung, And Blood Institute2012
- Clinical Trails In Myeloid Maliganancies With Molecularly Targeted TherapiesNational Cancer Institute2008–2012
- Aa&Mdsif Second Bone Marrow Failure Disease Scientific SymposiumNational Heart, Lung, And Blood Institute2009
- Core--Clinical Research Support ComponentNational Cancer Institute2002
- Protein Kinase C Based Antileukemic TherapyNational Cancer Institute1995–1999
- Differentiation Signal Transduction In Myeloid LeukemiaNational Cancer Institute1990–1994
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: